Enanta Pharmaceuticals (NASDAQ:ENTA) PT Raised to $50.00 at SVB Leerink

Enanta Pharmaceuticals (NASDAQ:ENTAGet Rating) had its price objective upped by SVB Leerink from $44.00 to $50.00 in a research note issued on Monday, MarketBeat reports. The brokerage presently has a “market perform” rating on the biotechnology company’s stock. SVB Leerink’s target price points to a potential downside of 16.75% from the stock’s previous close.

Several other equities analysts have also recently commented on ENTA. Roth Capital lowered their price target on shares of Enanta Pharmaceuticals from $101.00 to $70.00 in a report on Wednesday, May 11th. Evercore ISI upgraded shares of Enanta Pharmaceuticals from an “in-line” rating to an “outperform” rating and set a $62.00 price target on the stock in a report on Wednesday, July 6th. Robert W. Baird lowered their price target on shares of Enanta Pharmaceuticals from $130.00 to $90.00 and set an “outperform” rating on the stock in a report on Thursday, May 19th. Oppenheimer lowered their price target on shares of Enanta Pharmaceuticals from $70.00 to $45.00 and set an “outperform” rating on the stock in a report on Friday, May 20th. Finally, Royal Bank of Canada upped their price objective on shares of Enanta Pharmaceuticals from $64.00 to $67.00 and gave the stock a “sector perform” rating in a report on Friday, July 1st. One analyst has rated the stock with a sell rating, two have assigned a hold rating and five have assigned a buy rating to the company’s stock. According to data from MarketBeat.com, Enanta Pharmaceuticals currently has an average rating of “Moderate Buy” and an average target price of $73.75.

Enanta Pharmaceuticals Trading Up 0.6 %

ENTA stock opened at $60.06 on Monday. Enanta Pharmaceuticals has a one year low of $37.59 and a one year high of $102.00. The firm has a market capitalization of $1.24 billion, a PE ratio of -10.88 and a beta of 0.58. The firm has a 50-day moving average of $46.32 and a two-hundred day moving average of $57.67.

Enanta Pharmaceuticals (NASDAQ:ENTAGet Rating) last posted its quarterly earnings results on Monday, May 9th. The biotechnology company reported ($1.63) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($1.43) by ($0.20). The company had revenue of $18.72 million during the quarter, compared to analysts’ expectations of $20.40 million. Enanta Pharmaceuticals had a negative return on equity of 28.80% and a negative net margin of 122.68%. During the same period last year, the company earned ($1.09) earnings per share. On average, equities research analysts anticipate that Enanta Pharmaceuticals will post -5.58 earnings per share for the current year.

Hedge Funds Weigh In On Enanta Pharmaceuticals

A number of hedge funds and other institutional investors have recently bought and sold shares of the business. Victory Capital Management Inc. boosted its stake in Enanta Pharmaceuticals by 18.7% in the second quarter. Victory Capital Management Inc. now owns 19,123 shares of the biotechnology company’s stock valued at $904,000 after acquiring an additional 3,009 shares during the last quarter. Russell Investments Group Ltd. boosted its stake in Enanta Pharmaceuticals by 39.5% in the second quarter. Russell Investments Group Ltd. now owns 20,721 shares of the biotechnology company’s stock valued at $978,000 after acquiring an additional 5,872 shares during the last quarter. Arizona State Retirement System boosted its stake in Enanta Pharmaceuticals by 6.9% in the second quarter. Arizona State Retirement System now owns 5,285 shares of the biotechnology company’s stock valued at $250,000 after acquiring an additional 340 shares during the last quarter. Assenagon Asset Management S.A. boosted its stake in Enanta Pharmaceuticals by 1.5% in the second quarter. Assenagon Asset Management S.A. now owns 137,266 shares of the biotechnology company’s stock valued at $6,489,000 after acquiring an additional 2,080 shares during the last quarter. Finally, Strs Ohio boosted its stake in Enanta Pharmaceuticals by 5.7% in the second quarter. Strs Ohio now owns 14,900 shares of the biotechnology company’s stock valued at $704,000 after acquiring an additional 800 shares during the last quarter. 98.87% of the stock is owned by institutional investors.

Enanta Pharmaceuticals Company Profile

(Get Rating)

Enanta Pharmaceuticals, Inc, a biotechnology company, discovers and develops small molecule drugs for the treatment of viral infections and liver diseases. Its research and development disease targets include respiratory syncytial virus, SARS-CoV-2, human metapneumovirus, and hepatitis B virus. The company has a collaborative development and license agreement with Abbott Laboratories to identify, develop, and commercialize HCV NS3 and NS3/4A protease inhibitor compounds, including paritaprevir and glecaprevir for the treatment of chronic hepatitis C virus.

Featured Stories

Analyst Recommendations for Enanta Pharmaceuticals (NASDAQ:ENTA)

Receive News & Ratings for Enanta Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Enanta Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.